Clinical trials
High Bleeding Risk clinical trials
Below are recruiting high bleeding risk clinical trials, each written for real people, not researchers. We’re tracking 141 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05198960RecruitingPhase 3
Blood thinner drugs vs aspirin to prevent clot problems
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
AngersAges 18 years+ - NCT05208307RecruitingPhase 2
Belantamab with pomalidomide and dexamethasone after high-risk myeloma transplant
This Phase 2 study tests a treatment combination (belantamab mafodotin, pomalidomide, and dexamethasone) for high-risk multiple myeloma after an autologous stem cell transplant. It aims to improve disease control in people who have certain genetic features or aggressive disease behavior.
Atlanta, GeorgiaAges 18 years+ - NCT05287321RecruitingPhase 3
Aspirin plus hydroxychloroquine to prevent preeclampsia in high-risk pregnancy
This trial tests whether adding aspirin and hydroxychloroquine can lower the risk of preeclampsia during pregnancy in people considered high-risk. If you qualify, you may be assigned to take the study medicines to help protect you and the baby.
SeoulAges 19–50 - NCT05407519RecruitingPhase 2
Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hefei, AnhuiAges 18–70 - NCT05445310RecruitingPhase 2
Taking furmonertinib after lung surgery for high-risk EGFR cancer
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
BeijingAges 18–75 - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05686434RecruitingPhase 2
Osimertinib after surgery for early-stage EGFR-mutated lung cancer
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05895136RecruitingPhase 2
Albumin plus blood thinner for severe cirrhosis after hospital recovery
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
ClichyAges 18–80 - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT05936606Recruiting
Personalized blood thinner choice after stent placement
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
SeoulAges 19–80 - NCT06036446Recruiting
Late cerclage for preventing early birth in high-risk pregnancies
This trial tests if placing a stitch in the cervix (cerclage) between 24 and 27 weeks of pregnancy can help prevent preterm birth in women whose cervix is short. It may be an option for those who find out late in pregnancy that they are at risk.
Charlotte, North CarolinaAges 18–50 - NCT06143969Recruiting
Ultrasound-guided clot-dissolving treatment for intermediate-high risk pulmonary embolism
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
Milan, ItaliaAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06208462RecruitingPhase 2
Combination therapy before surgery for high-risk bile duct cancer
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Nanjing, JiangsuAges 18–75 - NCT06295497Recruiting
Lung cancer screening for non-smokers with a family history
This study tests an artificial intelligence device to screen for lung cancer in people who have never smoked but have a close family member with lung cancer. If you are between 50 and 75 and fit for possible surgery, you may be able to join.
Hong KongAges 50–75 - NCT06319846RecruitingPhase 3
Tirofiban for recent mild stroke or TIA with narrowed brain artery
This trial tests the drug tirofiban (a blood thinner) to prevent another stroke in people who have had a mild stroke or high-risk TIA and have a narrowed artery in the brain. It must be started within 24 hours of symptoms.
Harbin, HeilongjiangAges 40 years+ - NCT06362746RecruitingPhase 3
Staphylokinase for intermediate high-risk pulmonary embolism
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
Barnaul, Altayskiy KrayAges 18 years+ - NCT06437353RecruitingPhase 2
Surufatinib combo for first-line and maintenance in high-risk ovarian cancer
This trial tests a combination of drugs (Surufatinib with carboplatin/paclitaxel) as first treatment for high-risk ovarian cancer, followed by a different combination (Surufatinib with olaparib) to keep the cancer from coming back. It aims to see if these targeted therapies work better than the standard approach.
Hefei, AnhuiAges 18–75 - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06498622RecruitingPhase 2
Liver cancer relapse prevention after surgery
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Fuyang, AnhuiAges 18–80 - NCT06573008RecruitingPhase 3
Testing GP681 Tablets for Flu in High-Risk Patients
This study tests an oral tablet called GP681 for people with flu who are at higher risk of serious complications. It compares the new drug to a placebo to see if it helps reduce symptoms faster.
ChizhouAges 12 years+ - NCT06601127RecruitingPhase 2
Tiprogrel for recent minor stroke or high-risk TIA
This trial tests a new anti-platelet drug called Tiprogrel to prevent another stroke in people who recently had a minor stroke or a transient ischemic attack (TIA) with certain artery narrowing or plaques. It aims to see if this medicine is safe and works better than current treatments.
Shenyang, LiaoningAges 40 years+
Hear when a new High Bleeding Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high bleeding risk?
- Yes. Clin2 currently lists 141 recruiting high bleeding risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high bleeding risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high bleeding risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.